A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations
Open accessPublished version of a preprint
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Although the value of proteomics has been demonstrated, cost and scale are typically prohibitive, and gene expression profiling remains dominant for characterizing cellular responses to perturbations. However, high-throughput sentinel assays provide an opportunity for proteomics to contribute at a meaningful scale. We present a systematic library resource (90 drugs × 6 cell lines) of proteomic signatures that measure changes in the reduced-representation phosphoproteome (P100) and changes in epigenetic marks on histones (GCP). A majority of these drugs elicited reproducible signatures, but notable cell line- and assay-specific differences were observed. Using the "connectivity" framework, we compared signatures across cell types and integrated data across assays, including a transcriptional assay (L1000). Consistent connectivity among cell types revealed cellular responses that transcended lineage, and consistent connectivity among assays revealed unexpected associations between drugs. We further leveraged the resource against public data to formulate hypotheses for treatment of multiple myeloma and acute lymphocytic leukemia. This resource is publicly available at https://clue.io/proteomics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Self-citationLamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Self-citationSkyline: an open source document editor for creating and analyzing targeted proteomics experiments
MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M., Finney, G. L., Frewen, B., Kern, R., Tabb, D. L., Liebler, D. C., & MacCoss, M. J. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq054 · Cited by 4,697
Self-citationRole of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
Self-citationAntitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · cited 1×
“At the same time, many established protein-targeting drugs lack clear mechanistic insight and may harbor unexpected phosphosignaling and epigenetic activities that would be useful in repurposing efforts (Gupta et al., 2013; Singhal et al., 1999).”
BackgroundComparing protein abundance and mRNA expression levels on a genomic scale
Greenbaum, D. (2003) · Genome biology · doi:10.1186/gb-2003-4-9-117 · Cited by 1,692 · cited 2×
“Early studies recognized apparent discordance between mRNA and protein levels on a large scale (Greenbaum et al., 2003), and current studies suggest that the correlation coefficient between mRNA and protein levels is only 0.”
BackgroundInfluentialProteogenomics connects somatic mutations to signalling in breast cancer
CPTAC, N., Mertins, P., Mani, D. R., Ruggles, K. V., Gillette, M. A., Clauser, K. R., Wang, P., Wang, X., Qiao, J. W., Cao, S., et al. (2016) · Nature · doi:10.1038/nature18003 · Cited by 1,676
Self-citationKuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596 · cited 1×
“Additionally, it is the core catalytic member of the Polycomb Repressive Complex 2 (PRC2), whose activity has been associated with repression of genes and marking of inactive chromatin (Kuzmichev et al., 2002).”
BackgroundWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Research works printed but not linked: 57
- Abelin, 2016, Reduced-representation phosphosignatures measured by quantitative targeted ms capture cellular states and enable large-scale comparison of drug-induced phenotypes, Mol. Cell. Proteomics, 15, 1622, 10.1074/mcp.M116.058354 · DOI · Paper page
- Alizadeh, 2000, Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, 403, 503, 10.1038/35000501 · DOI · Paper page
- Araf, 2016, Epigenetic dysregulation in follicular lymphoma, Epigenomics, 8, 77, 10.2217/epi.15.96 · DOI
- Ashenden, 2017, An in vivo functional screen identifies JNK signaling as a modulator of chemotherapeutic response in breast cancer, Mol. Cancer Ther., 16, 1967, 10.1158/1535-7163.MCT-16-0731 · DOI
- Aumann, 2014, Somatic alterations and dysregulation of epigenetic modifiers in cancers, Biochem. Biophys. Res. Commun., 455, 24, 10.1016/j.bbrc.2014.08.004 · DOI
- Barbie, 2009, Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature, 462, 108, 10.1038/nature08460 · DOI · Paper page
- Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, 483, 603, 10.1038/nature11003 · DOI · Paper page
- Baur, 2006, Therapeutic potential of resveratrol: the in vivo evidence, Nat. Rev. Drug Discov., 5, 493, 10.1038/nrd2060 · DOI · Paper page
- Bhanu, 2016, Histone modification profiling reveals differential signatures associated with human embryonic stem cell self-renewal and differentiation, Proteomics, 16, 448, 10.1002/pmic.201500231 · DOI
- Bian, 2014, An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome, J. Proteomics, 96, 253, 10.1016/j.jprot.2013.11.014 · DOI · Paper page
- Bittner, 2000, Molecular classification of cutaneous malignant melanoma by gene expression profiling, Nature, 406, 536, 10.1038/35020115 · DOI · Paper page
- Bridges, 2016, MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells, Oncotarget, 7, 71660, 10.18632/oncotarget.12311 · DOI
- Bryant, 2014, Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers, BMC Cancer, 14, 570, 10.1186/1471-2407-14-570 · DOI
- Ciceri, 2014, Dual kinase-bromodomain inhibitors for rationally designed polypharmacology, Nat. Chem. Biol., 10, 305, 10.1038/nchembio.1471 · DOI · Paper page
- Clark, 2000, Genomic analysis of metastasis reveals an essential role for RhoC, Nature, 406, 532, 10.1038/35020106 · DOI · Paper page
- Creech, 2015, Building the Connectivity Map of epigenetics: chromatin profiling by quantitative targeted mass spectrometry, Methods, 72, 57, 10.1016/j.ymeth.2014.10.033 · DOI · Paper page
- Dawson, 2012, Targeting epigenetic readers in cancer, N. Engl. J. Med., 367, 647, 10.1056/NEJMra1112635 · DOI · Paper page
- Fabian, 2005, A small molecule-kinase interaction map for clinical kinase inhibitors, Nat. Biotechnol., 23, 329, 10.1038/nbt1068 · DOI · Paper page
- Golub, 1999, Molecular classification of cancer: class discovery and class prediction by gene expression monitoring, Science, 286, 531, 10.1126/science.286.5439.531 · DOI · Paper page
- Gräff, 2009, Epigenetic dysregulation in cognitive disorders, Eur. J. Neurosci., 30, 1, 10.1111/j.1460-9568.2009.06787.x · DOI · Paper page
- Gupta, 2013, Cancer drug discovery by repurposing: teaching new tricks to old dogs, Trends Pharmacol. Sci., 34, 508, 10.1016/j.tips.2013.06.005 · DOI · Paper page
- Iacovelli, 2015, Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia, Oncotarget, 6, 32089, 10.18632/oncotarget.5156 · DOI
- Iorio, 2016, A landscape of pharmacogenomic interactions in cancer, Cell, 166, 740, 10.1016/j.cell.2016.06.017 · DOI · Paper page
- Jaffe, 2013, Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia, Nat. Genet., 45, 1386, 10.1038/ng.2777 · DOI · Paper page
- Jenuwein, 2001, Translating the histone code, Science, 293, 1074, 10.1126/science.1063127 · DOI · Paper page
- Kelly, 2010, Epigenetic modifications as therapeutic targets, Nat. Biotechnol., 28, 1069, 10.1038/nbt.1678 · DOI · Paper page
- Kulej, 2015, Characterization of histone post-translational modifications during virus infection using mass spectrometry-based proteomics, Methods, 90, 8, 10.1016/j.ymeth.2015.06.008 · DOI
- Lamb, 2003, JunD mediates survival signaling by the JNK signal transduction pathway, Mol. Cell, 11, 1479, 10.1016/S1097-2765(03)00203-X · DOI · Paper page
- Laubach, 2017, Deacetylase inhibitors: an advance in myeloma therapy?, Expert Rev. Hematol., 10, 229, 10.1080/17474086.2017.1280388 · DOI
- Lee, 2008, Ahnak protein activates protein kinase C (PKC) through dissociation of the PKC-protein phosphatase 2A complex, J. Biol. Chem., 283, 6312, 10.1074/jbc.M706878200 · DOI
- Li, 2017, Characterization of human cancer cell lines by reverse-phase protein arrays, Cancer Cell, 31, 225, 10.1016/j.ccell.2017.01.005 · DOI · Paper page
- Luense, 2016, Comprehensive analysis of histone post-translational modifications in mouse and human male germ cells, Epigenetics Chromatin, 9, 24, 10.1186/s13072-016-0072-6 · DOI
- Martin, 2005, The diverse functions of histone lysine methylation, Nat. Rev. Mol. Cell Biol., 6, 838, 10.1038/nrm1761 · DOI · Paper page
- Ntziachristos, 2016, Emerging concepts of epigenetic dysregulation in hematological malignancies, Nat. Immunol., 17, 1016, 10.1038/ni.3517 · DOI · Paper page
- Ott, 2012, BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia, Blood, 120, 2843, 10.1182/blood-2012-02-413021 · DOI · Paper page
- Parker, 2009, Supervised risk predictor of breast cancer based on intrinsic subtypes, J. Clin. Oncol., 27, 1160, 10.1200/JCO.2008.18.1370 · DOI · Paper page
- Peck, 2010, SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2, Mol. Cancer Ther., 9, 844, 10.1158/1535-7163.MCT-09-0971 · DOI · Paper page
- Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093 · DOI · Paper page
- Qin, 2015, DNA methylation requires a DNMT1 ubiquitin interacting motif (UIM) and histone ubiquitination, Cell Res., 25, 911, 10.1038/cr.2015.72 · DOI · Paper page
- Rohban, 2017, Systematic morphological profiling of human gene and allele function via Cell Painting, Elife, 6, 10.7554/eLife.24060 · DOI · Paper page
- Shannon, 2003, Cytoscape: a software environment for integrated models of biomolecular interaction networks, Genome Res., 13, 2498, 10.1101/gr.1239303 · DOI · Paper page
- Sharma, 2014, Panorama: a targeted proteomics knowledge base, J. Proteome Res., 13, 4205, 10.1021/pr5006636 · DOI · Paper page
- Shi, 2016, Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia, J. Hematol. Oncol., 9, 12, 10.1186/s13045-016-0241-x · DOI
- Sidoli, 2015, Sequential window acquisition of all theoretical mass spectra (SWATH) analysis for characterization and quantification of histone post-translational modifications, Mol. Cell. Proteomics, 14, 2420, 10.1074/mcp.O114.046102 · DOI · Paper page
- Smith, 2017, Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the Connectivity Map, PLoS Biol., 15, e2003213, 10.1371/journal.pbio.2003213 · DOI · Paper page
- Steiner, 2017, Carfilzomib boosted combination therapy for relapsed multiple myeloma, Onco. Targets Ther., 10, 895, 10.2147/OTT.S102756 · DOI
- Suzuki, 2006, Pvclust: an R package for assessing the uncertainty in hierarchical clustering, Bioinformatics, 22, 1540, 10.1093/bioinformatics/btl117 · DOI · Paper page
- Tasian, 2017, Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia, Blood, 129, 177, 10.1182/blood-2016-05-707653 · DOI · Paper page
- van der Maaten, 2008, Visualizing data using t-SNE, J. Mach. Learn. Res., 9, 2579
- Wagle, 2011, Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling, J. Clin. Oncol., 29, 3085, 10.1200/JCO.2010.33.2312 · DOI · Paper page
- Wendling, 2013, Resveratrol, a sirtuin 1 activator, increases IL-6 production by peripheral blood mononuclear cells of patients with knee osteoarthritis, Clin. Epigenetics, 5, 10, 10.1186/1868-7083-5-10 · DOI
- Wernig, 2008, Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera, Cancer Cell, 13, 311, 10.1016/j.ccr.2008.02.009 · DOI · Paper page
- Whitesell, 2003, The stress response: implications for the clinical development of hsp90 inhibitors, Curr. Cancer Drug Targets, 3, 349, 10.2174/1568009033481787 · DOI · Paper page
- Witzig, 2015, The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma, Blood, 126, 328, 10.1182/blood-2015-02-629543 · DOI
- Wu, 2015, FDA-approved small-molecule kinase inhibitors, Trends Pharmacol. Sci., 36, 422, 10.1016/j.tips.2015.04.005 · DOI · Paper page
- Yazgan, 2002, Regulation of two JunD isoforms by Jun N-terminal kinases, J. Biol. Chem., 277, 29710, 10.1074/jbc.M204552200 · DOI · Paper page
- Zhou, 2013, Toward a comprehensive characterization of a human cancer cell phosphoproteome, J. Proteome Res., 12, 260, 10.1021/pr300630k · DOI · Paper page
Cited by
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
Self-citationData‐independent acquisition‐based SWATH ‐ MS for quantitative proteomics: a tutorial
Ludwig, C., Gillet, L., Rosenberger, G., Amon, S., Collins, B. C., & Aebersold, R. (2018) · Molecular Systems Biology · doi:10.15252/msb.20178126 · Cited by 1,002
Proteogenomic and metabolomic characterization of human glioblastoma
Wang, L.-B., Karpova, A., Gritsenko, M. A., Kyle, J. E., Cao, S., Li, Y., Rykunov, D., Colaprico, A., Rothstein, J. H., Hong, R., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.006 · Cited by 661
Self-citationImage-based profiling for drug discovery: due for a machine-learning upgrade?
Chandrasekaran, S. N., Ceulemans, H., Boyd, J. D., & Carpenter, A. E. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00117-w · Cited by 389
A Curated Resource for Phosphosite-specific Signature Analysis
Krug, K., Mertins, P., Zhang, B., Hornbeck, P., Raju, R., Ahmad, R., Szucs, M., Mundt, F., Forestier, D., Jane-Valbuena, J., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.tir118.000943 · Cited by 338
Self-citationIlluminating the dark phosphoproteome
Needham, E. J., Parker, B. L., Burykin, T., James, D. E., & Humphrey, S. J. (2019) · Science Signaling · doi:10.1126/scisignal.aau8645 · Cited by 334
A White-Box Machine Learning Approach for Revealing Antibiotic Mechanisms of Action
Yang, J. H., Wright, S. N., Hamblin, M., McCloskey, D., Alcantar, M. A., Schrübbers, L., Lopatkin, A. J., Satish, S., Nili, A., Palsson, B. O., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.016 · Cited by 321
Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer
Petralia, F., Tignor, N., Reva, B., Koptyra, M., Chowdhury, S., Rykunov, D., Krek, A., Ma, W., Zhu, Y., Ji, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.044 · Cited by 317
“05) were then mapped to the P100 peptide probes (Litichevskiy et al., 2018) and were used for subsequent analysis.”
LINCS Data Portal 2.0: next generation access point for perturbation-response signatures
Stathias, V., Turner, J., Koleti, A., Vidovic, D., Cooper, D., Fazel-Najafabadi, M., Pilarczyk, M., Terryn, R., Chung, C., Umeano, A., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkz1023 · Cited by 161
Down-syndrome-induced senescence disrupts the nuclear architecture of neural progenitors
Meharena, H. S., Marco, A., Dileep, V., Lockshin, E. R., Akatsu, G. Y., Mullahoo, J., Watson, L. A., Ko, T., Guerin, L. N., Abdurrob, F., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2021.12.002 · Cited by 92
Self-citationProteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling
Kabella, N., Bayer, F. P., Stamatiou, K., Abele, M., Sakhteman, A., Chang, Y.-C., Wagner, V., Gabriel, A., Krumm, J., Reinecke, M., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adt6552 · Cited by 8
Metadata
- Authors
- Litichevskiy, L., Peckner, R., Abelin, J. G., Asiedu, J. K., Creech, A. L., Davis, J. F., Davison, D., Dunning, C. M., Egertson, J. D., Egri, S., Gould, J., Ko, T., Johnson, S. A., Lahr, D. L., Lam, D., Liu, Z., Lyons, N. J., Lu, X., MacLean, B. X., Mungenast, A. E., Officer, A., Natoli, T. E., Papanastasiou, M., Patel, J., Sharma, V., Toder, C., Tubelli, A. A., Young, J. Z., Carr, S. A., Golub, T. R., Subramanian, A., MacCoss, M. J., Tsai, L.-H., & Jaffe, J. D.
- Venue
- Cell Systems
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 6
- Issue
- 4
- Pages
- 424-443.e7
- ISSN
- 2405-4712 (ISSN-L)
- OpenAlex
- W2751974426
- Cited by
- 87
- References
- 16
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- NIH (U54HG008097, U54HG008699)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.